L'Agcm has decided not to start an investigation into the operation with which Lidea, Italian holding company of the Dr. Max group, will acquire exclusive control of Italian Pharmacies. For the Authority there are no significant risks for competition: even in the areas where the networks overlap, the post-operation market shares generally remain below 20%. A limit, instead, to the non-compete agreements: they can be considered accessories to the…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
L'Agcm has decided not to start an investigation into the operation with which Lidea, Italian holding company of the Dr. Max group, will acquire exclusive control of Italian Pharmacies. For the Authority there are no significant risks for competition: even in the areas where the networks overlap, the post-operation market shares generally remain below 20%. A limit, instead, to the non-compete agreements: they can be considered accessories to the…